Moreover, the GLUT1 inhibitor STF‐31 could lower glycolysis levels and promote the phosphorylation of eIF2α, inducing the ICD of HCC cells along with increased expression of calreticulin and decreased expression of CD47. This evidence concerns the gene EIF2A and hepatocellular carcinoma.